Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer

C Perez-Ramirez, M Canadas-Garre, MÁ Molina… - … Research/Reviews in …, 2017 - Elsevier
Although platinum-based chemotherapy remains the standard treatment for advanced
NSCLC patients, clinical outcomes are poor and most patients develop high-grade toxicities …
被引用次数：41 相关文章

[引用][C] Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer

C Pérez-Ramírez, M Cañadas-Garre… - … Research/Reviews in …, 2017 - cir.nii.ac.jp
Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of
non-small cell lung cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …

Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer

C Pérez-Ramírez, M Cañadas-Garre… - … research/Reviews in …, 2017 - pure.qub.ac.uk
Although platinum-based chemotherapy remains the standard treatment for advanced
NSCLC patients, clinical outcomes are poor and most patients develop high-grade toxicities …

Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer.

C Pérez-Ramírez, M Cañadas-Garre… - … research. Reviews in …, 2016 - europepmc.org
Although platinum-based chemotherapy remains the standard treatment for advanced
NSCLC patients, clinical outcomes are poor and most patients develop high-grade toxicities …
[PDF] qub.ac.uk

[PDF][PDF] Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer

C Pérez-Ramírez, M Cañadas-Garre, MÁ Molina… - 2017 - pureadmin.qub.ac.uk
Although platinum-based chemotherapy remains as a standard treatment for advanced
NSCLC patients, the clinical outcomes are poor and most patients develop high-grade …
[PDF] academia.edu

[PDF][PDF] Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer

C Pérez-Ramírez, M Cañadas-Garre, MÁ Molina… - 2017 - academia.edu
Although platinum-based chemotherapy remains as a standard treatment for advanced
NSCLC patients, the clinical outcomes are poor and most patients develop high-grade …
[PDF] core.ac.uk

[PDF][PDF] Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer

C Pérez-Ramírez, M Cañadas-Garre, MÁ Molina… - 2017 - core.ac.uk
Although platinum-based chemotherapy remains as a standard treatment for advanced
NSCLC patients, the clinical outcomes are poor and most patients develop high-grade …

Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer

C Pérez-Ramírez, M Cañadas-Garre… - … Reviews in Mutation …, 2017 - ui.adsabs.harvard.edu
Although platinum-based chemotherapy remains the standard treatment for advanced
NSCLC patients, clinical outcomes are poor and most patients develop high-grade toxicities …

Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer

C Pérez-Ramírez, M Cañadas-Garre… - … Research/Reviews in …, 2017 - infona.pl
Although platinum-based chemotherapy remains the standard treatment for advanced
NSCLC patients, clinical outcomes are poor and most patients develop high-grade toxicities …

Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer

C Pérez-Ramírez, M Cañadas-Garre… - Mutation research …, 2017 - pubmed.ncbi.nlm.nih.gov
Although platinum-based chemotherapy remains the standard treatment for advanced
NSCLC patients, clinical outcomes are poor and most patients develop high-grade toxicities …